We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

215 hedge funds and large institutions have $2.23B invested in Ligand Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 59 increasing their positions, 89 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $23.5M | Put options by funds: $9.54M

138% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 21

29% more capital invested

Capital invested by funds: $1.73B → $2.23B (+$496M)

15% more funds holding

Funds holding: 187 → 215 (+28)

34% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 89

40% less funds holding in top 10

Funds holding in top 10: 10 → 6 (-4)

Holders
215
Holders Change
+28
Holders Change %
+14.97%
% of All Funds
5.79%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.16%
New
50
Increased
59
Reduced
89
Closed
21
Calls
$23.5M
Puts
$9.54M
Net Calls
+$14M
Net Calls Change
+$14.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$32.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$25.8M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$19.7M
4
GIM
Granahan Investment Management
Massachusetts
+$18.6M
5
JHIU
Janus Henderson Investors US
Colorado
+$10.8M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$24.1M
2
BI
BVF Inc
California
-$20.6M
3
Invesco
Invesco
Georgia
-$18M
4
RIM
RS Investment Management
California
-$17.9M
5
NCGI
Next Century Growth Investors
Minnesota
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
26
Macquarie Group
Australia
$22M -$1.06M -19,364 -5%
FMA
27
Fiduciary Management Associates
Illinois
$21.4M -$10M -183,739 -35%
JHIU
28
Janus Henderson Investors US
Colorado
$20.2M +$10.8M +197,423 +160%
PAM
29
Panagora Asset Management
Massachusetts
$17.1M -$291K -5,339 -2%
NCGI
30
Next Century Growth Investors
Minnesota
$16.5M -$13.7M -251,231 -49%
Wells Fargo
31
Wells Fargo
California
$15.7M -$1.26M -23,014 -8%
CS
32
Credit Suisse
Switzerland
$13.7M +$3.81M +69,874 +47%
EAM
33
Eagle Asset Management
Florida
$12.7M +$1.46M +26,774 +15%
Geode Capital Management
34
Geode Capital Management
Massachusetts
$12.6M +$701K +12,853 +7%
GC
35
Guggenheim Capital
Illinois
$11.9M +$799K +14,645 +8%
Charles Schwab
36
Charles Schwab
California
$11.9M -$10.2M -186,400 -50%
EAM
37
Eventide Asset Management
Massachusetts
$11.5M – – –
Principal Financial Group
38
Principal Financial Group
Iowa
$11.3M -$185K -3,382 -2%
ACM
39
Ashford Capital Management
Delaware
$10.7M -$131K -2,405 -1%
NAM
40
Nichols Asset Management
Massachusetts
$10.3M -$4.81M -88,247 -35%
Prudential Financial
41
Prudential Financial
New Jersey
$10.2M -$1.72M -31,515 -16%
Renaissance Technologies
42
Renaissance Technologies
New York
$9.7M +$8.4M +154,039 New
AAM
43
AMI Asset Management
California
$9.62M +$8.34M +152,904 New
RHJA
44
Rice Hall James & Associates
California
$9.58M -$825K -15,113 -9%
OAM
45
Oberweis Asset Management
Illinois
$9.41M -$2.81M -51,424 -26%
Goldman Sachs
46
Goldman Sachs
New York
$9.31M -$24.1M -442,007 -75%
UBS AM
47
UBS AM
Illinois
$9.12M +$6.7M +122,740 +552%
CAM
48
Cortina Asset Management
Wisconsin
$8.23M -$1.72M -31,481 -19%
Fisher Asset Management
49
Fisher Asset Management
Washington
$8.13M -$114K -2,084 -2%
American Century Companies
50
American Century Companies
Missouri
$7.84M -$1.41M -25,848 -17%
1
2
3 4 5

LGND Hedge Fund Activity: Q2 2015 in Review

215 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2015, worth a combined $2.23B — up 29% from $1.73B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new LGND positions and 21 closed out — a net gain of 29 holders — while 59 added to existing stakes and 89 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $32.1M. The largest seller was Goldman Sachs, cutting an estimated $24.1M.

  • 215 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2015, up from 187 in Q1 2015.
  • Funds reported $2.23B of Ligand Pharmaceuticals stock for Q2 2015, up 29% quarter-over-quarter.
  • 50 funds opened new Ligand Pharmaceuticals positions in Q2 2015 and 21 closed out, a net change of +29 holders.
  • The largest Ligand Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $32.1M added.
  • The largest Ligand Pharmaceuticals seller in Q2 2015 was Goldman Sachs, an estimated $24.1M sold.

Based on aggregated 13F filings for Q2 2015.